Anti-PTK7 Antibody-drug Conjugate SKB518 clinical trials
Also written SKB518.
Its developmentBy Sichuan Kelun Pharmaceutical, step by step3 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PTK7 Antibody-drug Conjugate SKB518 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PTK7 Antibody-drug Conjugate SKB518 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2024 (1)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-PTK7 Antibody-drug Conjugate SKB518.
- Feb 2027A Study of SKB518 in Patients With Lung CancerPhase 2 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses Anti-PTK7 Antibody-drug Conjugate SKB518 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant TumorsRecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07448922Written as SKB518 for injectionHow we know
- A Study of SKB518 in Patients With Advanced Solid TumorsRecruitingPhase 1Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT06428331Written as SKB518 for injectionHow we know
- A Study of SKB518 in Patients With Lung CancerRecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07019675Written as SKB518How we know